A bioavailability score

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3164-3170

  Martin, Yvonne C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOLYTE; ANION; CATION;

ARTICLE; CELL STRAIN CACO 2; CHEMICAL BOND; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MEDICAL LITERATURE; NONHUMAN; PH; RAT; SCORING SYSTEM; SURFACE CHARGE;

ANIMALS; ANIONS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; HUMANS; PERMEABILITY; PROBABILITY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS;

EID: 18244370266     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0492002     Document Type: Article

References (54)

1. Van De Waterbeemd, H.; Gifford, E. Admet in Silico Modelling: Towards Prediction Paradise? Nature Rev. Drug Discovery 2003, 2, 192-204.
2. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput Screening - Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes. J. Med. Chem. 1998, 41, 1007-1010.
3. Artursson, P.; Karlsson, J. Correlation between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (Caco-2) Cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885.
4. Overton, E. Osmotic Properties of Cells in the Bearing on Toxicology and Pharmacy. Z. Phys. Chem. 1897, 22, 189-209.
5. Meyer, H. Zur Theorie Der Alkolnarkose I. Welche Eigenschaft Der Anaesthetica Bedingt Ihre Narkotische Wirkung? Arch. Exp. Pathol. Pharmakol. 1899, 42, 109-118.
6. Clark, D. E. Prediction of Intestinal Absorption and Blood-Brain Barrier Penetration by Computational Methods. Comb. Chem. High Throughput Screening 2001, 4, 477-496.
7. Hirono, S.; Nakagome, I.; Hirano, H.; Matsushita, Y.; Yoshii, F. et al. Non-Congeneric Structure-Pharmacokinetic Property Correlation Studies Using Fuzzy Adaptive Least-Squares: Oral Bioavailability. Biol. Pharm. Bull. 1994, 17, 306-309.
8. Wessel, M. D.; Jurs, P. C.; Tolan, J. W.; Muskal, S. M. Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure. J. Chem. Inform. Comput. Sci. 1998, 38, 726-735.
9. Yoshida, F.; Topliss, J. G. QSAR Model for Drug Human Oral Bioavailability. J. Med. Chem. 2000, 43, 2575-2585.
10. Egan, W. J.; Merz, K. M.; Baldwin, J. J. Prediction of Drug Absorption Using Multivariate Statistics. J. Med. Chem. 2000, 43, 3867-3877.
11. Wolohan, P. R. N.; Clark, R. D. Predicting Drug Pharmacokinetic Properties Using Molecular Interaction Fields and Simca. J. Comput.-Aided Mol. Des. 2003, 17, 65-76.
12. Oprea, T. I.; Zamora, I.; Ungell, A. L. Pharmacokinetically Based Mapping Device for Chemical Space Navigation. J. Comb. Chem. 2002, 4, 258-266.
13. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
14. Navia, M. A.; Chaturvedi, P. R. Design Principles for Orally Bioavailable Drugs. Drug Discovery Today 1996, 1, 179-189.
15. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W. et al. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem., 2002, 45, 2615-2623.
16. Hill, A. P.; Hyde, R. M.; Robertson, A. D.; Wollard, P. M.; Glen, R. et al. Oral Delivery of 5-HT1D Receptor Agonists: Towards the Discovery of 311c90, a Novel Anti-Migraine Agent. Headache 1994, 34, 308.
17. Rosenberg, S. H.; Spina, K. P.; Condon, S. L.; Polakowski, J.; Yao, Z. et al. Studies Directed toward the Design of Orally Active Renin Inhibitors. 2. Development of the Efficacious, Bioavailable Renin Inhibitor (2s)-2- Benzyl-3- [[(1-Methylpiperazin-4-Yl)-Sulfonyl]Propionyl]-3-Thiazol-4-Yl- L-Alanine Amide of (2s,3r,-4s)-2-Amino-1-Cyclohexyl-3,4-Dihydroxy-6- Methylheptane (a-72517). J. Med. Chem. 1993, 36, 460-467.
18. Camenisch, G.; Folkers, G.; Vandewaterbeemd, H. Shapes of Membrane Permeability-Lipophilicity Curves -Extension of Theoretical Models with an Aqueous Pore Pathway. Eur. J. Pharm. Sci. 1998, 6, 321-329.
19. Sawada, G. A.; Barsuhn, C. L.; Lutzke, B. S.; Houghton, M. E.; Padbury, G. E. et al. Increased Lipophilicity and Subsequent Cell Partitioning Decrease Passive Transcellular Diffusion of Novel, Highly Lipophilic Antioxidants. J. Pharmacol. Exp. Ther. 1999, 288, 1317-1326.
20. Paterson, D. A.; Conradi, R. A.; Hilgers, A. R.; Vidmar, T. J.; Burton, P. S. A Non-Aqueous Partitioning System for Predicting the Oral Absorption Potential of Peptides. Quant. Structure-Act. Relat. 1994, 13, 4-10.
21. Burton, P. S.; Conradi, R. A.; Ho, N. F. H.; Hilgers, A. R.; Borchardt, R. T. How Structural Features Influence the Biomembrane Permeability of Peptides. J. Pharm. Sci. 1998, 85, 1336-1340.
22. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans. Pharm. Res. 1997, 14, 568-571.
23. Norinder, U.; Osterberg, T.; Artursson, P. Theoretical Calculation and Prediction of Caco-2 Cell Permeability Using Molsurf Parametrization and Pls Statistics. Pharm. Res. 1997, 14, 1786-1791.
24. Stenberg, P.; Luthman, K.; Artursson, P. Prediction of Membrane Permeability to Peptides from Calculated Dynamic Molecular Surface Properties. Pharm. Res. 1999, 16, 205-212.
25. Norinder, U.; Osterberg, T.; Artursson, P. Theoretical Calculation and Prediction of Intestinal Absorption of Drugs in Humans Using Molsurf Parametrization and Pls Statistics. Eur. J. Pharm. Sci. 1999, 8, 49-56.
26. Tamai, I.; Nakanishi, T.; Nakahara, H.; Sai, Y.; Ganapathy, V. et al. Improvement of L-Dopa Absorption by Dipeptidyl Derivation, Utilizing Peptide Transporter Pept1. J. Pharm. Sci. 1998, 87, 1542-1546.
27. Cerius 2; Accelrys: San Diego, CA.
28. iDEA pkExpress; Lion Bioscience AG: Heidelberg, Germany.
29. Absolv; Sirius Analytical Instruments Ltd: East Sussex UK.
30. Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J. et al. Evaluation of Human Intestinal Absorption Data and Subsequent Derivation of a Quantitative Structure-Activity Relationship (QSAR) with Abraham Descriptors (Vol 90, Pg 749, 2001). J. Pharm. Sci. 2002, 91, 605.
31. Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J. et al. Evaluation of Human Intestinal Absorption Data and Subsequent Derivation of a Quantitative Structure-Activity Relationship (QSAR) with the Abraham Descriptors. J. Pharm. Sci. 2001, 90, 749-784.
32. QikProp; Schrödinger, Inc.
33. QMPRPLUS; Simulations plus, inc.: Lancaster, CA 93534-2902.
34. Volsurf; Tripos, Inc.: St. Louis, MO.
35. Cruciani, G.; Pastor, M.; Guba, W. Volsurf: A New Tool for the Pharmacokinetic Optimization of Lead Compounds. Eur. J. Pharm. Sci. 2000, 11, S29-S39.
36. Oraspotter; zyxbio: Cleveland, OH.
37. Clark, D. E. Rapid Calculation of Polar Molecular Surface Area and Its Application to the Prediction of Transport Phenomena. 1. Prediction of Intestinal Absorption. J. Pharm. Sci. 1999, 88, 807-814.
38. Clark, D. E. Rapid Calculation of Polar Molecular Surface Area and Its Application to the Prediction of Transport Phenomena. 2. Prediction of Blood-Brain Barrier Penetration. J. Pharm. Sci. 1999, 88, 815-821.
39. Norinder, U.; Haeberlein, M. Computational Approaches to the Prediction of the Blood-Brain Distribution. Adv. Drug Delivery Rev. 2002, 54, 291-313.
40. Feher, M.; Sourial, E.; Schmidt, J. M. A Simple Model for the Prediction of Blood-Brain Partitioning. Intl. J. Pharm. 2000, 201, 239-247.
41. Kempf, D. J.; Marsh, K. C.; Paul, D. A.; Knigge, M. F.; Norbeck, D. W. et al. Antiviral and Pharmacokinetic Properties of C2 Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease. Antimicrob. Agents Chemother. 1991, 35, 2209-2214.
42. Benet, L. Z.; Øie, S.; Schwartz, J. B. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th ed.; McGraw-Hill: New York, 1996; pp 1707-1792.
43. Bertz, R. J.; Granneman, G. R. Use of in Vitro and in Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin. Pharmacokinet. 1997, 32, 210-258.
44. Sietsema, W. K. The Absolute Oral Bioavailabilty of Selected Drugs. Intl. J. Clin. Pharmacol, Ther. Toxicol. 1989, 27, 179-211.
45. Hoekman, D.; Leo, A. J. CLOGP; 4.3 ed.; Biobyte: Claremont, CA.
46. ADME Batch; Pharma Algorithms: Toronto, Canada.
47. Pearlman, R. S. Savol3; College of Pharmacy, The University of Texas at Austin, Austin, TX. Pearlman@vax.phr.utexas.edu.: Austin, TX.
48. Daylight Chemical Information Systems. Manual to Version 4.61; 4.62 ed.; Daylight Chemical Information Systems: Mission Viejo, CA 92691.
49. Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do Structurally Similar Molecules Have Similar Biological Activity? J. Med. Chem. 2002, 45, 4350-4358.
50. Leo, A. Medchem 2002 Database; Biobyte: Claremont, CA.
51. ADME Boxes; 1.0 ed.; Pharma Algorithms: Toronto, Canada.
52. Jaffe, A. J.; Spirer, H. F. Misused Statistics: Straight Talk for Twisted Numbers; Marcel Dekker. New York, 1987; pp 146-149.
53. Palm, K.; Luthman, K.; Ungell, A. L.; Strandlund, G.; Artursson, P. Correlation of Drug Absorption with Molecular-Surface Properties. J. Pharm. Sci. 1988, 85, 32-39.
54. Egan, W. J.; Lauri, G. Prediction of Intestinal Permeability. Adv. Drug Delivery Rev. 2002, 54, 273-289.